Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a small molecule belonging to the class of phenyl-substituted triazolopyrimidines. It features a benzoic acid moiety attached to a triazolopyrimidine core with amino and hydroxy functional groups. The structure suggests it is an experimental or research chemical rather than an approved pharmaceutical agent. There are no known clinical indications or approvals for this compound as of now. Its mechanism of action and biological targets have not been characterized in publicly available drug databases[2][4]. It has been referenced in chemical libraries such as ZINC15 Pharmaceuticals and listed in DrugBank (DB01906), but without detailed pharmacological data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-(5-amino-7-hydroxy-(1,2,3)triazolo(4,5-d)pyrimidin-2-yl)benzoic acid.